Biogen Inc.
03/10/2026 | Press release | Distributed by Public on 03/10/2026 14:11
Biogen to Participate in the Stifel 2026 Virtual CNS Forum
Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that Diana Gallagher, M.D., Head of Clinical Development, MS&I and AD, and Stephanie Fradette, PharmD, Head of the Neuromuscular Development Unit, will participate in a fireside chat during the Stifel 2026 Virtual CNS Forum. The webcast will be live on Wednesday, March 18, 2026, at 9:30 a.m. ET. To access the live webcast, please visit the Investors section of Biogen's website at investors.biogen.com. An archived version of the webcast will be available for at least 30 days following the presentation.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.
Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442
Biogen Inc. published this content on March 10, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 10, 2026 at 20:12 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]